 Effect suramin human prostate cancer cells vitro Suramin polyanionic compound known antiparasitic activity adrenocorticolytic primates clinical efficacy treatment patients metastatic prostate cancer refractory conventional hormonal manipulation activity suramin prostate cancer biology effect drug plasma adrenal androgens patients human prostate adenocarcinoma cell lines DU LNCaP-FGC cancer patients suramin approximate decline androstenedione dehydroepiandrosterone dehydroepiandrosterone sulfate levels drug colony formation cell lines concentrations achievable humans excessive drug-related toxicity presence micrograms./ml growth stimulatory effect testosterone basic fibroblast growth factor epidermal growth factor cellular concentration suramin exposure single dose increases time cell lines LNCaP-FGC levels drug cellular levels suramin androgen growth factor sensitivity sensitivity drug concentrations prostatic acid phosphatase prostatic specific antigen LNCaP-FGC cells cell culture medium presence levels suramin manner decrease cell number suramin androgens adrenocorticolytic effect capable direct inhibitory effect cell proliferation prostate cancer cells cellular level growth stimulatory effects exogenous testosterone basic fibroblast growth factor